6628 Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Transcenta Holding Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.66 |
| 52 Week High | HK$4.00 |
| 52 Week Low | HK$0.50 |
| Beta | -0.10 |
| 1 Month Change | -14.29% |
| 3 Month Change | -36.54% |
| 1 Year Change | -74.71% |
| 3 Year Change | -92.82% |
| 5 Year Change | n/a |
| Change since IPO | -95.02% |
Recent News & Updates
Shareholder Returns
| 6628 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 8.2% | -3.9% | -0.5% |
| 1Y | -74.7% | -5.7% | 19.9% |
Return vs Industry: 6628 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 6628 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 6628 volatility | |
|---|---|
| 6628 Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 6628 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6628's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 200 | Xueming Qian | www.transcenta.com |
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States. The company develops MSB2311, a humanized PD-L1 monoclonal antibody (mAb) candidate for TMB-H solid tumors; TST001, a humanized claudin 18.2 mAb candidate for solid tumors, such as gastric and gastroesophageal cancer; TST005, a PD-L1/TGF-ß bi-functional protein candidate for solid tumors; TST002 (Blosozumab), a humanized sclerostin mAb candidate for osteoporosis; and TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate for IgA kidney diseases. It also develops TST010, an antibody candidate targeting regulatory T cells to enhance T cell mediated tumor killing; TST003, a regulatory protein expressed by stromal cells and tumor cells, including colon, prostate, gastric, lung, esophageal, pancreatic, and breast cancers; TST006, a bi-specific claudin 18.2/PD-L1 antibody for solid tumors; TST008, a bi-functional antibody for MASP-2 and BAFF for autoimmune diseases; MSB0254, a humanized VEGFR-2 mAb candidate for solid tumors; MSB2311, A humanized PD-L1 mAb candidate for solid tumors; TST012 and TST013, an ADC candidate targeting biomarker expressing gastric cancer and other solid tumors; and TST801, a bifunctional fusion protein for autoimmune diseases.
Transcenta Holding Limited Fundamentals Summary
| 6628 fundamental statistics | |
|---|---|
| Market cap | HK$267.00m |
| Earnings (TTM) | -HK$382.22m |
| Revenue (TTM) | HK$23.80m |
11.2x
P/S Ratio-0.7x
P/E RatioIs 6628 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6628 income statement (TTM) | |
|---|---|
| Revenue | CN¥22.33m |
| Cost of Revenue | CN¥16.52m |
| Gross Profit | CN¥5.81m |
| Other Expenses | CN¥364.46m |
| Earnings | -CN¥358.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 26.02% |
| Net Profit Margin | -1,606.18% |
| Debt/Equity Ratio | 37.2% |
How did 6628 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Transcenta Holding Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bing Zhao | China Renaissance Securities |
| Ziyi Chen | Goldman Sachs |
| null null | Guoyuan Securities (HK) Ltd |